| 8581387 |
Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, Wells W, Barth R, Deo Y, Fisher J, et al.: Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother. 1995 Oct;4(5):471-5.
|
4(0,0,0,4) |
Details |
| 11777265 |
Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R: Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61.
PATIENTS AND METHODS: Dendreon Corporation has designed three therapeutic vaccines using blood-derived dendritic cells loaded ex vivo with antigen: Provenge for prostate cancer; Mylovenge for multiple myeloma and other B-cell malignancies; and APC8024 for cancers expressing the HER-2/neu proto-oncogene. |
1(0,0,0,1) |
Details |